Stockreport

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects [Yahoo! Finance]

Redhill Biopharma Ltd. - American Depositary Shares  (RDHL) 
US:NASDAQ Investor Relations: ir.redhillbio.com/investor-relations
PDF oncology support, acute gastroenteritis and gastritis, IBS-D and GLP-1 /GIP-associated gastrointestinal (GI) side effects Largey de-risked, RHB-102 development is supp [Read more]